scholarly journals Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions

2018 ◽  
Vol 33 (2) ◽  
pp. 312-317 ◽  
Author(s):  
P. Calzavara-Pinton ◽  
N. Tanova ◽  
P. Hamon
Keyword(s):  
Actinic Keratosis ◽  
Treatment Costs ◽  
Topical Treatments ◽  
Cancerization Field

Long-term efficacy of a new medical device containing Fernblock® and DNA repair enzyme complex in the treatment and prevention of cancerization field in patients with actinic keratosis.

2019 ◽  
Vol 2 (02) ◽  
pp. 80-89
Author(s):  
Blanca De Unamuno Bustos ◽  
Natalia Chaparr´´o Aguilera ◽  
Inmaculada Azorín García ◽  
Anaid Calle Andrino ◽  
Margarita Llavador Ros ◽  
...  
Keyword(s):  
Dna Damage ◽  
Dna Repair ◽  
Medical Device ◽  
Actinic Keratosis ◽  
Statistical Significance ◽  
Dna Lesions ◽  
Enzyme Complex ◽  
Repair Enzyme ◽  
P53 Expression ◽  
Cancerization Field

Actinic keratosis (AKs) are part of the cancerization field, a region adjacent to AKs containing subclinical and histologically abnormal epidermal tissue due to Ultraviolet (UV)-induced DNA damage. The photoproducts as consequence of DNA damage induced by UV are mainly cyclobutane pyrimidine dimers (CPDs). Fernblock® demonstrated in previous studies significant reduction of the number of CPDs induced by UV radiation. Photolyases are a specific group of enzymes that remove the major UV-induced DNA lesions by a mechanism called photo-reactivation. A monocentric, prospective, controlled, and double blind interventional study was performed to evaluate the effect of a new medical device (NMD) containing a DNA-repair enzyme complex (photolyases, endonucleases and glycosilases), a combination of UV-filters, and Fernblock® in the treatment of the cancerization field in 30 AK patients after photodynamic therapy. Patients were randomized into two groups: patients receiving a standard sunscreen (SS) andpatients receiving the NMD. Clinical, dermoscopic, reflectance confocal microscopy (RCM) and histological evaluations were performed. An increase of AKs was noted in all groups after three months of PDT without significant differences between them (p=0.476). A significant increase in the number of AKs was observed in SS group after six (p=0.026) and twelve months of PDT (p=0.038); however, this increase did not reach statistical significance in the NMD group. Regarding RCM evaluation, honeycomb pattern assessment after twelve months of PDT showed significant differences in the extension and grade of the atypia in the NMD group compared to SS group (p=0.030 and p=0.026, respectively). Concerning histopathological evaluation, keratinocyte atypia grade improved from baseline to six months after PDT in all the groups, with no statistically significant differences between the groups. Twelve months after PDT, p53 expression was significantly lower in the NMD group compared to SS group (p=0.028). The product was well-tolerated, with no serious adverse events reported. Our results provide evidence of the utility of this NMD in the improvement of the cancerization field and in the prevention of the development of new AKs.  

scholarly journals Topical treatments and photodynamic therapy for actinic keratosis of the face and scalp

2019 ◽  
Author(s):  
Kelly Foley ◽  
Aditya K Gupta ◽  
George Martin ◽  
John A Tweed ◽  
Elmer Villanueva ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Actinic Keratosis ◽  
The Face ◽  
Topical Treatments

Evaluation of the costs of topical treatments for actinic keratosis based on lesion response and the affected area

2018 ◽  
Vol 153 (6) ◽  
Author(s):  
Piergiacomo Calzavara-Pinton ◽  
Cristina Zane ◽  
Mariachiara Arisi ◽  
Pol-Antoine Hamon ◽  
Neda T. Tanova
Keyword(s):  
Actinic Keratosis ◽  
Affected Area ◽  
Topical Treatments

An economic evaluation of topical treatments for actinic keratosis

2009 ◽  
Vol 20 (5) ◽  
pp. 266-275 ◽  
Author(s):  
Dominic Muston ◽  
Anthony Downs ◽  
Vincent Rives
Keyword(s):  
Economic Evaluation ◽  
Actinic Keratosis ◽  
Topical Treatments

scholarly journals Non-adherence to topical treatments for actinic keratosis

2013 ◽  
pp. 35 ◽  
Author(s):  
Alison Carr ◽  
Bav Shergill ◽  
Simon Zokaie
Keyword(s):  
Actinic Keratosis ◽  
Topical Treatments

Adherence to topical treatments for actinic keratosis

2016 ◽  
Vol 175 (5) ◽  
pp. 872-872
Author(s):  
L.A. Cardwell ◽  
S.R. Feldman
Keyword(s):  
Actinic Keratosis ◽  
Topical Treatments

Patients' perceptions of topical treatments of actinic keratosis

2013 ◽  
Vol 25 (5) ◽  
pp. 375-379 ◽  
Author(s):  
Solveig Esmann ◽  
Gregor B. E. Jemec
Keyword(s):  
Actinic Keratosis ◽  
Topical Treatments

Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study

2016 ◽  
Vol 175 (5) ◽  
pp. 1094-1096 ◽  
Author(s):  
S. Erntoft ◽  
J.M. Norlin ◽  
C. Pollard ◽  
T.L. Diepgen
Keyword(s):  
Actinic Keratosis ◽  
Diary Study ◽  
Patient Reported ◽  
Topical Treatments

scholarly journals Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting

10.36469/9879 ◽  
2014 ◽  
Vol 2 (1) ◽  
pp. 1-14
Author(s):  
Michael Willis ◽  
Sandra Erntoft ◽  
Sofie Persson ◽  
Jenny M. Norlin ◽  
Ulf Persson
Keyword(s):  
Willingness To Pay ◽  
Actinic Keratosis ◽  
Topical Treatment ◽  
Treatment Duration ◽  
The United States ◽  
Tolerability Profile ◽  
Ingenol Mebutate ◽  
Skin Reactions ◽  
Local Skin ◽  
Topical Treatments

Background: Currently available topical treatments for actinic keratosis (AK) adversely affect patients’ quality of life because of long treatment durations and long-lasting local skin reactions (LSRs), which may result in poor treatment adherence and patient outcomes. Ingenol mebutate gel, a recently introduced treatment for AK, is administered for 2 or 3 days, and LSR’s are predicable in onset and duration. Objectives: The objective of the study was to estimate the value of ingenol mebutate gel’s shorter treatment duration and tolerability profile to potential patients, versus existing topical treatments (imiquimod 3.75%, imiquimod 5% and diclofenac 3%) in the United States. Methods: The open-ended Contingent Valuation (CV) approach was used to estimate incremental willingness-to-pay (WTP) for ingenol mebutate gel rather than treatment with imiquimod 5%, imiquimod 3.75% and diclofenac 3%. Profiles for each therapy differed in regards to treatment duration, time-to-LSR resolution, and price. Subjects were asked to state their maximum out-of-pocket WTP to receive ingenol mebutate gel instead of each of the three alternatives. Results: 103 subjects provided usable answers. Between 48% and 63% of subjects were willing to pay extra to gain access to treatment with the ingenol mebutate gel profile instead of the comparators, and the mean incremental WTP ranged from $475 to $518. Subjects with experience of topical treatment stated higher WTP for accessing ingenol mebutate gel. Subjects whose most bothersome AK area was the full scalp or forehead also claimed higher WTP for ingenol mebutate gel. Conclusions: Patients diagnosed with AK indicated an unmet need for fast-acting topical treatment with shorter LSR resolution time.

scholarly journals Long-Term Efficacy of a New Medical Device Containing Fernblock® and DNA Repair Enzyme Complex in the Treatment and Prevention of Cancerization Field in Patients with Actinic Keratosis

2019 ◽  
Vol 10 (4) ◽  
Author(s):  
Blanca de Unamuno Bustos ◽  
Natalia Chaparro Aguilera ◽  
Inmaculada Azorin Garcia ◽  
Anaid Calle Andrino ◽  
Margarita Llavador Ros ◽  
...  
Keyword(s):  
Dna Repair ◽  
Medical Device ◽  
Actinic Keratosis ◽  
Enzyme Complex ◽  
Repair Enzyme ◽  
Term Efficacy ◽  
Treatment And Prevention ◽  
Cancerization Field
Sign in / Sign up

Export Citation Format

Share Document